EFFICACY RESULTS

VYXEOS DEMONSTRATED SUPERIORITY IN OVERALL SURVIVAL COMPARED TO CONVENTIONAL CHEMOTHERAPY IN PATIENTS AGED 60-75 WITH HIGH-RISK AML1*†

PRIMARY ENDPOINT

OVERALL SURVIVAL IN THE ITT POPULATION1

efficacy-results-graph-1
Adapted from the VYXEOS Product Monograph.
efficacy-results-graph-1
Adapted from the VYXEOS Product Monograph.

More patients treated with VYXEOS reached 1-, 2- year survival landmarks than with conventional chemotherapy1,2*

efficacy-results-new-graph2-en
Adapted from Lancet, et al (2018) and the VYXEOS Product Monograph.
efficacy-results-new-graph2-en
Adapted from Lancet, et al (2018) and the VYXEOS Product Monograph.

PATIENTS TREATED WITH VYXEOS ACHIEVED SIGNIFICANTLY GREATER RESPONSE RATES VS CONVENTIONAL CHEMOTHERAPY1*

SECONDARY ENDPOINT

RESPONSE RATES IN PATIENTS TREATED WITH VYXEOS VS CONVENTIONAL CHEMOTHERAPY1*

efficacy-results-graph-3-desk
Adapted from the VYXEOS Product Monograph.
PG-15-03
Adapted from the VYXEOS Product Monograph.

Consider what complete remission could mean for your AML patients

LONGER OVERALL SURVIVAL WITHOUT HSCT

Median OS

vyxeos-survival-desk
vyxeos-survival-mob
efficacy-results-graph-4-desk
efficacy-results-graph-4-mob

ITT: Intent-to-treat

CI: Confidence interval

HR: Hazard ratio

HSCT: Hematopoietic stem cell transplantation

CRi: Complete response with incomplete platelet or neutrophil recovery

OR: Odds ratio

*Conventional chemotherapy includes the 7+3/5+2 regimen for induction and consolidation, using cytarabine and daunorubicin.2

†High-risk AML defined as t-AML or AML-MRC.

References: 1. Current VYXEOS® Product Monograph, Jazz Pharmaceuticals Canada, Inc. 2. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol 2018;36:2684–2692. 3. Lin TL, Rizzieri DA,Ryan DH, et al. Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Adv 2021;5(6):1719–1728. 4. Jazz Pharmaceuticals. Data on File. Early mortality.

CA-VYX-2400012-E | March 2024